Clinical Trial Update: A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors [Phase 1]

View source ↗

Summary

This early-phase trial assesses the safety and feasibility of combining irinotecan and thalidomide in patients with recurrent central nervous system tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Central Nervous System Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Thalidomide (thalidomide)

Snippet

Sponsor: University of New Mexico | Conditions: Brain and Nervous System, Cancer | Phase 1 | Status: COMPLETED